Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?

    Everolimus immunosuppression in kidney transplantation: optimal strategy?

What is the

Oliver Witzke, Claudia Sommerer, Wolfgang Arns PII: DOI: Reference:

S0955-470X(15)00061-0 doi: 10.1016/j.trre.2015.09.001 YTRRE 393

To appear in:

Transplantation Reviews

Please cite this article as: Witzke Oliver, Sommerer Claudia, Arns Wolfgang, Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?, Transplantation Reviews (2015), doi: 10.1016/j.trre.2015.09.001

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?

RI P

T

Oliver Witzke1, Claudia Sommerer2, Wolfgang Arns3

SC

1. Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

NU

2. Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany

MA

3. Department of Nephrology, Cologne Merheim Medical Center, University

Contact for correspondence

PT

Prof. Dr. med. Oliver Witzke

ED

Witten/Herdecke, Germany

CE

Department of Nephrology, University Hospital Essen, University of Duisburg-Essen Hufelandstr. 55, D-45122 Essen, Germany

AC

Tel: +49 (2017236552) Email: [email protected]

Conflicts of interest

Oliver Witzke has received research grants for clinical studies, speaker’s fees, honoraria and travel expenses from Amgen, Astellas, Bristol-Myers Squibb, Chiesi, Novartis, Roche, Pfizer and Sanofi. Claudia Sommerer and Wolfgang Arns have received research support from Novartis.

Funding. Support for a medical writer (Caroline Dunstall) was provided by Novartis Pharma GmbH.

1

ACCEPTED MANUSCRIPT Abbreviations

area under the time-concentration curve

BMI

body mass index

BPAR

biopsy-proven acute rejection

CMV

cytomegalovirus

CNI

calcineurin inhibitor

CsA

cyclosporine

eGFR

estimated glomerular filtration rate

HLA

human leukocyte antigen

IL-2

interleukin 2

MMF

mycophenolate mofetil

MPA

mycophenolic acid

mTOR

mammalian target of rapamycin

PRA

panel reactive antibody

AC

CE

PT

ED

MA

NU

SC

RI P

T

AUC

2

ACCEPTED MANUSCRIPT Abstract

Two main everolimus-based strategies have been pursued to facilitate calcineurin

RI P

T

inhibitor (CNI) reduction after kidney transplantation: (i) everolimus with reduced CNI exposure from time of transplant (ii) pre-emptive introduction of everolimus with CNI

SC

reduction or withdrawal at some point post-transplant. Randomized trials have shown no loss of immunosuppressive efficacy for everolimus (targeting 3–8ng/mL) with reduced-

NU

exposure CNI versus standard-exposure CNI and mycophenolic acid (MPA) in low-tomoderate risk patients. Renal function has tended to be numerically, but not significantly,

MA

higher with everolimus and reduced-CNI versus MPA and standard-CNI. One study which used very low CsA exposure in everolimus-treated patients reported a substantial

ED

improvement in estimated GFR compared to controls, but this requires confirmation. Pre-emptive conversion to everolimus at three to six months after kidney transplantation

PT

significantly improves long-term renal function, but with an increased rate of mild acute

CE

rejection. Earlier conversion (up to two months post-transplant) can lead to an increase in rejection risk, while later conversion (more than six months post-transplant) is

AC

unproductive unless baseline renal function is good. This article considers the risks and benefits associated with either strategy, and reviews specific clinical situations that influence the optimal approach in individual patients. The balance of evidence suggests two options. De novo everolimus with reduced CNI, steroids and induction therapy ensures immunosuppressive efficacy in low- or standard-risk populations, and investigations into this strategy are ongoing. Conversion to everolimus with CNI withdrawal between three and six months post-transplant offers a long-term renoprotective effect if baseline graft function is good.

Keywords: everolimus, mTOR inhibitor, conversion, CNI, withdrawal, kidney transplantation,

3

ACCEPTED MANUSCRIPT Introduction

Recent years have seen a growing emphasis on immunosuppressive strategies which

RI P

T

reduce exposure to calcineurin inhibitors (CNI) after kidney transplantation. A recent meta-analysis has suggested that minimizing CNI exposure by administering various

SC

adjunctive therapies or induction regimens is associated with improved graft survival [1]. One of the most intensive areas of research has concerned use of the mammalian target

NU

of rapamycin (mTOR) inhibitor everolimus to facilitate CNI sparing [2, 3]. Everolimus blocks growth factor-driven T-cell proliferation while CNI agents inhibit early interleukin 2

MA

(IL-2) gene transcription, a synergism that permits a substantial reduction in CNI exposure without loss of efficacy [4, 5]. Since the nephrotoxicity associated with CNI

ED

agents does not occur under mTOR inhibitors, a key goal is to avoid chronic CNI-related histological damage to the graft. In addition, there is increasing interest in other potential

PT

benefits of mTOR inhibitor therapy relating to its antiproliferative activity, notably

CE

reducing tumor growth and de novo malignancies [3, 6–8], its cardioprotective effects [3,

AC

9–11] and evidence for a lower frequency of cytomegalovirus (CMV) infections [12].

Two main everolimus-based strategies for CNI reduction have been pursued: (i) everolimus with reduced CNI exposure from time of transplant, i.e. de novo use, and (ii) pre-emptive introduction of everolimus with CNI withdrawal (or reduction) at some point post-transplant, without a clinical imperative. There are also reports of series in which patients have been switched from CNI-based immunosuppression to everolimus in response to clinical events, but randomized trials are lacking. A fourth option – entirely CNI-free everolimus-based immunosuppression from time of transplantation – has been largely discounted based on data showing that a CNI-free regimen with the mTOR inhibitor sirolimus is associated with high rates of acute rejection and treatment discontinuation [13, 14].

4

ACCEPTED MANUSCRIPT This article compares results achieved with different approaches to everolimus therapy after kidney transplantation, and considers special clinical circumstances that can

De novo everolimus with reduced-exposure CNI

RI P

T

influence the choice of strategy.

SC

Randomized trials have shown no loss of immunosuppressive efficacy when everolimus is administered with reduced-exposure CNI versus standard-exposure CNI in de novo

NU

kidney transplant populations at low or moderate immunological risk [15–17] (Table 1).

MA

While none of these studies study observed a statistically significant benefit for renal function in the CNI-reduction treatment groups, renal function was numerically higher for the everolimus-treated cohort versus the standard CNI group in three of the trials [15–

ED

17]. Based on these comparative studies, and two pivotal trials that assessed different

PT

everolimus doses in combination with reduced-exposure cyclosporine (CsA) [24], CNI

CE

exposure is now routinely lowered in everolimus-treated patients.

The US92 study, reported in abstract form only so far, included kidney transplant

AC

patients at all levels of immunological risk randomized to reduced-exposure or standardexposure tacrolimus, both with everolimus [18]. The rate of biopsy-proven acute rejection (BPAR) was higher in the reduced-tacrolimus arm, a fact likely accounted for by below-target levels of tacrolimus in approximately 30% of patients and a higher proportion of at-risk patients (deceased or extended criteria donor, or ≥3 human leukocyte antigen [HLA] mismatches) in the reduced-tacrolimus group [18]. Everolimus with reduced-exposure CNI from time of transplant has not been assessed in a controlled trial of a high-risk population.

5

ACCEPTED MANUSCRIPT The question of how everolimus with reduced CNI compares to a conventional regimen of mycophenolic acid (MPA) and standard-exposure CNI has been addressed in three

T

large randomized trials of de novo kidney transplant patients [19, 20, 22]. The largest of

RI P

these (A2309) was a 24-month, multicenter, open-label study in which de novo primary kidney transplant recipients were randomized to everolimus targeting a trough

SC

concentration of 3–8ng/mL or 6–12ng/mL with reduced-exposure CsA, or to MPA (mycophenolate mofetil [MMF] 1.44g/day) with standard-exposure CsA [20]. All patients

NU

received induction with basiliximab. The primary efficacy endpoint (a composite of

MA

treated BPAR, graft loss, death or loss to follow-up) was statistically non-inferior in both everolimus groups versus MPA (Table 1), a finding confirmed at month 24 [21]. Mean estimated glomerular filtration rate (eGFR) at month 12 was also noninferior in the

ED

everolimus groups versus the MPA group at month 12 [20], and remained similar at

PT

month 24 [21]. Of note, patients who had eGFR <60mL/min/1.73m2 at month 1 (i.e. chronic kidney disease [CKD] stage ≤3), 20% of those randomized to everolimus 3–

CE

8ng/mL achieved eGFR >60mL/min/1.73m2 by month 12 versus 12% in the MPA group [20]. Discontinuations due to adverse events were significantly more frequent in the

AC

everolimus treatment arms (Table 1), a difference that arose largely during the first year post-transplant [20].

Mean CNI exposure was more than 60% lower in the everolimus treatment groups versus the control arm of study A2309 by month 24 post-transplant [21]. A post hoc analysis showed that the lowest rates of renal dysfunction (based on eGFR or serum creatinine, or the presence of proteinuria) were observed when CsA concentration was below 100ng/mL [25], consistent with the dose-dependent nature of CNI-related nephrotoxicity [26]. Two studies have explored very low CNI exposure in patients using relatively high everolimus exposure [19, 23]. In the EVEREST study, everolimus 8–

6

ACCEPTED MANUSCRIPT 12ng/mL with a CsA C2 target range of 150–300ng/mL versus a typical range of 500– 700ng/mL found no significant benefit for renal function versus a more usual reduced-

T

CsA protocol (C2 500–700ng/mL), although the rate of BPAR was not compromised [23].

RI P

Interestingly, however, Bertoni et al used a slightly higher CsA target level (C2 250– 300ng/mL) with everolimus 8–12ng/mL and found eGFR to be substantially and

SC

significantly higher in the everolimus cohort at month 12 compared to a conventional regimen of MPA with standard CNI [19] (Table 1). This regimen has not been examined

NU

in other trials, but may be of interest for future studies attempting to achieve a significant

MA

renal benefit. Currently, however, everolimus in the range 3–8ng/mL appears to offer the best balance for efficacy and safety in de novo kidney transplant patients receiving reduced CNI [25]. In practice, targeting the higher end of this range (6–8ng/mL) in the

ED

first three months post-transplant, then tapering 4-6 during months 4 to 6 with 3–4ng/mL

PT

subsequently may be helpful, but this is based on empiric experience and has not been

CE

assessed in a controlled trial.

Overall, the available data indicate that everolimus targeting 3–8ng/mL can achieve at

AC

least 60% reduction in maintenance concentrations of CNI without loss of efficacy in de novo kidney transplant patients at low to moderate immunological risk. Within the duration of published trials, this regimen has shown a small numerical benefit for renal function versus a standard CNI-based regimen that only reached significance when very low CsA exposure was achieved [19]. It should be noted that randomized trials of early steroid withdrawal (7–14 days post-transplant) in patients receiving a de novo regimen of everolimus with reduced CNI have shown an increased risk of acute rejection [27, 28].

It should also be borne in mind that comparative studies assessing de novo everolimus with reduced CNI have largely used concomitant CsA. Given the known drug-drug interactions between everolimus and CsA, it is possible that combined therapy with

7

ACCEPTED MANUSCRIPT tacrolimus may be preferable. In the ongoing TRANSFORM study, de novo kidney transplant patients will be stratified by tacrolimus or CsA therapy, then randomized to

T

everolimus with reduced-exposure CNI or MPA with standard-exposure CNI [29]. The

RI P

study is recruiting over 2,000 de novo kidney transplant patients and in addition to providing a well-powered comparison between the two treatment groups will permit a

SC

comparison of everolimus with reduced CsA versus reduced tacrolimus from time of

NU

transplant.

It must also be remembered that everolimus exposure is influenced by the choice of

MA

concomitant CNI i.e. tacrolimus or CsA, due to different pharmacokinetic interactions. Co-administration of CsA has been shown to increase the area under the time-

ED

concentration curve (AUC) for everolimus by two- to three-fold [30, 31]. Such an effect is absent, or much lower, during tacrolimus administration. A cross-study comparison

PT

had shown that in patients receiving tacrolimus, the everolimus should be 1.5 to 2-fold

CE

higher than in CsA-treated patients to achieve the same everolimus exposure [32]. An initial everolimus dose of 1.5mg bid is advised instead of the standard 0.75mg bid

AC

recommended with concomitant CsA [32].

Pre-emptive switch to everolimus

Several randomized trials have investigated the effect of introducing everolimus and withdrawing CNI therapy in kidney transplant populations with the goal of preserving long-term renal function (Table 2) [27, 33–37]. These studies excluded patients at high risk for rejection, based on panel reactive antibodies (PRA) level and/or certain types of acute rejection prior to switch. The time post-transplant at which CNI withdrawal was started varied markedly – from seven weeks [33] to a mean of almost seven years [36]. Studies of very early switch at seven weeks [33], or halving of CNI dose from two weeks

8

ACCEPTED MANUSCRIPT onwards with full withdrawal at month 2 [27] have shown a markedly high rate of BPAR at month 12 (27.5% and 31%, respectively), even when higher concentrations of

T

everolimus were used (6–10ng/mL). There may also be an increased risk of de novo

RI P

donor specific antibodies (DSA) and antibody-mediated rejection in patients switched

SC

early from CNI therapy to everolimus in a steroid-free regimen [38].

Two large studies have both demonstrated significantly improved renal function when

NU

switch is initiated at months 3–4.5 [34, 39], although in the ZEUS trial there was a higher rate of mild BPAR episodes after CNI withdrawal compared to CNI continuation [34].

MA

Two studies of late conversion (APOLLO [mean seven years] [36] and ASCERTAIN [mean >5 years] [37]) showed no loss of efficacy after switch. In the APOLLO study,

ED

eGFR was significantly higher in the everolimus cohort at one year after conversion, with a mean between-group difference of 4.9mL/min/1.73m2 (p=0.030) [36]. The ASCERTAIN

PT

study showed stable function with or without switch to everolimus to 24 months, but no

CE

significant difference in favor of the everolimus-treated cohort [37]. However, the ASCERTAIN study showed that patients with well-preserved renal function at the time of

AC

late conversion (defined as creatinine clearance >50mL/min [Cockcroft-Gault]) achieved a significantly greater increase in measured GFR after CNI withdrawal than the control arm and that the difference at two years’ follow-up was clinically relevant (~11mL/min/1.73m2) [37]. For sirolimus, the CONVERT trial found that 40mL/min/1.73m2 (Nankivell) demarcated the threshold at which delayed conversion (at a mean of 3 years post-transplant) can lead to improved renal function [40].

Long-term follow-up data are available from four everolimus studies (three-year data for CENTRAL [41], five-year data for ZEUS [39], five-year data for APOLLO [42] and threeyear data for HERAKLES, in abstract form only [43] (Table 3). In the CENTRAL study, where conversion took place at week 7, the change of measured GFR between the

9

ACCEPTED MANUSCRIPT everolimus group and the control arm became non-significant by three years in the overall population [41]. For the subpopulation of patients who remained on study drug,

T

however, there was a marked superiority in the everolimus cohort: measured GFR

RI P

increased by a mean of 7.9mL/min by year 3 for everolimus-treated patients versus a decrease of 1.4mL/min in the standard CNI group (p=0.001). For the ZEUS and

SC

HERAKLES studies, where conversion to everolimus took place at month 4.5 and month 3 post-transplant, respectively, a clear renoprotective effect was maintained long-term

NU

with everolimus therapy compared to the CNI-based regimen across the study

MA

populations [39, 43] (Table 3). No between-group differences in the long-term rates of BPAR were observed [39, 41, 43]. In the APOLLO study (mean time to switch seven years), the difference in eGFR at five years after randomization showed a trend to

ED

superiority with everolimus overall (p=0.076), while for those patients who remained on

PT

study at five years eGFR was significantly higher in the everolimus-treated cohort versus

CE

the control arm (mean difference 8.2mL/min/1.73m2 p<0.001) [42].

One important factor is whether patients remain on everolimus after switching, or revert

AC

to CNI therapy. As might be expected when converting maintenance patients from their established regimen to a new agent, discontinuations due to adverse events are more frequent after switch to everolimus (Table 1). Overall results thus include a relatively high proportion of patients who converted back to the control regimen. When only those patients who remained on an everolimus-based, CNI-free regimen were analyzed, longterm data after early switch to everolimus in the CENTRAL study [41] or late switch in the APOLLO study [36] showed that conversion resulted in significantly better renal function than a conventional CNI-based regimen.

The HERAKLES study (so far published in abstract only) included a third treatment group (n=162), in which everolimus was initiated three months after transplantation and

10

ACCEPTED MANUSCRIPT CsA trough concentration was reduced to 50–75ng/mL [35]. In contrast to the CNI withdrawal arm, there was no significant difference in eGFR at three years compared to

T

the control group which continued to receive standard CsA with MPA [43]. The

RI P

ASCERTAIN trial also included a third arm in which patients were switched to everolimus with reduced CsA at a mean of 5.4 years post-transplant, and found no renal

SC

advantage [37]. Merely using everolimus to facilitate CsA dose reduction after employing conventional high CsA exposure in the first weeks, months or years after kidney

NU

transplantation does not appear to preserve renal function.

MA

Data from these randomized, controlled trials indicate that the optimal time for switching from CNI- to everolimus-based therapy is three to six months after kidney

ED

transplantation. After that time, only those patients with good baseline renal function and without pronounced proteinuria are likely to benefit from such a switch [37, 40]. A

PT

certain risk for additional mild acute rejection episodes and the fact that a sizeable

CE

proportion of patients that do not tolerate conversion to everolimus and revert to CNI therapy, should be kept in mind and balanced against the appeal of improved renal

AC

function.

Everolimus as rescue therapy

The literature includes a number of single-center reports from small series of maintenance kidney transplant patients who were switched from CNI therapy to everolimus in response to declining renal function [45, 46], malignant neoplasms or nonmelanoma skin cancer [47–50] or, more frequently, a mixture of indications but primarily renal deterioration or malignancy [51–54]. Studies of cohorts switched due to renal causes or for mixed reasons have consistently shown a significant improvement in renal function over follow-up periods ranging from six months to two years [45, 46, 51–54].

11

ACCEPTED MANUSCRIPT The benefit has been concentrated in patients with renal dysfunction at the time of switch [53, 54]. As seen in studies of pre-emptive conversion to everolimus, a shorter

T

time post-transplant was associated with greater renal benefit [52] and patients with very

RI P

poor baseline renal function tended to progress to end-stage renal disease [48]. Published cases of conversion from CNI therapy to everolimus in response to

SC

malignancy describe a variety of tumor types with varying surgical and adjunctive interventions, and have generally concluded that conversion is a valid therapeutic

NU

approach which helps to control disease progression [47–50].

MA

Clinical considerations influencing the type of everolimus regimen

Below, key clinical issues are discussed which could potentially influence the decision on

ED

whether to initiate everolimus de novo, or to undertake conversion from CNI therapy

PT

after the initial post-transplant period. While other potential positive effects are of interest, such as a possible cardioprotective effect of mTOR inhibition [55–58], and the

CE

risk of rare but severe side effects associated with mTOR inhibition such as pneumonitis

AC

[59–61] and angiodema [62, 63] should be borne in mind, they are currently unlikely to determine the prescribing strategy.

Immunological risk status. Randomized trials comparing de novo use of everolimus with reduced CNI versus a standard CNI-based regimen [19, 20, 22] have all excluded patients at high immunological risk based on various criteria including PRA status, extended cold ischemia time, chronic infection, retransplantation, older donor or recipient age, as well as positive T-cell cross match or ABO-incompatible transplants. All studies used basiliximab induction [19, 20, 22]. Thus, the efficacy of everolimus with reduced CNI from the time of transplant in high-risk patients or in the absence of IL-2 receptor antagonist induction has not yet been established in controlled trials. Similarly, switch

12

ACCEPTED MANUSCRIPT studies have typically excluded patients with high PRA levels and/or recent acute rejection other than mild episodes [27, 33–37].

RI P

T

Donor specific antibodies

At the preclinical level, one study in a porcine model of arterial transplantation observed

SC

that mTOR inhibition using sirolimus suppressed production of de novo donor-specific antibodies (DSA), an effect not seen when either CsA or tacrolimus were administered

NU

[64]. Confirmatory data, however, are lacking. In addition to the well-established

MA

inhibitory action of mTOR inhibitors on growth-factor-mediated proliferation of T-cells and T-helper cell signaling, an effect on de novo DSA could partly arise from an effect on B-cells. In vitro, everolimus has been found to inhibit both early and late stages of B-cell

ED

proliferation and differentiation into plasma cells, whereas MPA acted only in the early

PT

phase of the B-cell immune response [65].

CE

No randomized trial of everolimus which included development of de novo DSA as a prespecified endpoint has yet been published. A post-hoc analysis of the CENTRAL

AC

study, where patients were randomized at week 7 post-transplant to switch to everolimus or remain on CNI, the incidence of DSA was 15.0% in the everolimus group (9/60 patients) and 21.1% in the CNI control arm (12/57 patients) (p=0.600) [41]. A single center analysis, although reported only in abstract form to date [66], showed that at four years’ post-kidney transplant, the incidence of de novo DSA was 16.7% in a standardCsA treated group, 17.9% in a CNI-free group receiving everolimus, and 29.6% in patients receiving reduced CsA with everolimus cohort (29.6%). In the ZEUS study, the presence of DSA was virtually identical in the everolimus conversion arm compared to the control group (21.4% versus 20.0%) at five years post-transplant, but the pool of data was small (n=53) [39]. An association between everolimus and risk of developing

13

ACCEPTED MANUSCRIPT DSA has, however, been reported in a post hoc single-center analysis of 126 kidney transplant patients enrolled to one of two randomized trials (23.0% within an everolimus-

T

based CNI-free regimen versus 10.8% under standard CNI therapy) [38]. However, 60%

RI P

of patients were receiving no steroids. It seems likely that underimmunosuppression in the everolimus-treated patients contributed to the higher rate of de novo DSA, consistent

SC

with the observation that acute rejection was significantly associated with an increased

NU

risk for de novo DSA and antibody-mediated rejection [67].

Retrospective, single-center analyses of de novo DSA development in kidney transplant

MA

patients receiving everolimus have also been published, but the results are highly conflicting [68–70] and the different protocols and methodologies preclude firm

ED

conclusions. At this point, the evidence base regarding either DSA or antibody-mediated rejection in everolimus-treated patients is inadequate and evaluation of this important

PT

question is urgently required.

CE

Cytomegalovirus infection. CMV-specific CD8+ T-cell count appears to be higher under

AC

everolimus-based therapy compared to regimens containing MMF [71] which suppresses both T-cell and B-cell function [72]. Havenith et al studied 26 kidney transplant patients switched from CsA, MMF and steroids to everolimus, CsA or MMF (all with steroids) [71]. The CMV-specific CD8+ T-cell count increased significantly after switch from CsA/MMF to everolimus. Moreover, while everolimus does reduce CMVspecific CD8+ T-cell count versus no immunosuppression, interferon-γ secretion is unaffected [73], helping to maintain the anti-CMV immune response. Lastly, mTOR inhibitors block the phosphatidylinositol 3-kinase pathway, which is crucial for CMV replication [74].

14

ACCEPTED MANUSCRIPT There is convincing evidence that mTOR inhibitors may decrease the incidence and severity of CMV after kidney transplantation [75]. One study of maintenance kidney

T

transplant patients switched from CsA to everolimus found that counts of CMV-specific

RI P

T-lymphocytes increased significantly under everolimus therapy, and that in contrast to CNI therapy everolimus did not inhibit CMV-specific responses in vitro despite potent

SC

inhibition of alloresponses [71]. In a pooled analysis of three randomized trials of de novo kidney transplant patients receiving everolimus with reduced- or standard-exposure

NU

CsA, or MPA with standard CsA [20, 76, 77], Brennan and colleagues observed that the

MA

rates of CMV infection and CMV syndrome were significantly lower with everolimus versus MPA therapy even in patients receiving CMV prophylaxis [12]. Data from heart transplantation also indicates that the rate of CMV is significantly lower in patients

ED

receiving everolimus than azathioprine [78]. Prospective trials have not been undertaken

PT

with predefined CMV endpoints, but it seems feasible that choice of everolimus in high-

strategy.

CE

risk patients (recipient CMV-negative, donor CMV-positive) may be a useful preventative

AC

BK virus infection

There is also evidence indicating that everolimus with reduced CsA may be associated with a lower rate of BK infection compared to a standard CNI-MPA regimen [20, 79], possibly by suppressing viral replication via an inhibitory effect on the intracellular protein kinase pathways which are activated by BK virus infection [80]. The international A2309 study showed a lower incidence of BK viruria and viremia at one year posttransplant in 277 kidney patients randomized to de novo everolimus (targeting 3– 8ng/mL) with reduced CNI (0.7% and 1.1%, respectively) versus the control group of 277 patients given MMF with standard CNI (3.3% and 1.8%, respectively) [20]. At two years, BKV infection was observed in 0.7% of everolimus-treated patients versus 4.8% of

15

ACCEPTED MANUSCRIPT controls (p=0.004) [21]. A retrospective analysis of 296 kidney transplant patients at a single center has also reported a significantly lower rate of BK viremia under a de novo

T

regimen of everolimus and reduced CNI compared to MPA and standard CNI (5.9%

RI P

versus 52.2%, p=0.01), with a lower viral load in the everolimus-treated patients (mean 12.5 versus 1.8 x 104 copies/ml; p=0.01) [81]. Given the adverse impact of persistent BK

SC

viremia on graft function and survival after kidney transplantation [82], these encouraging results could contribute to arguments in favor of de novo initiation of

NU

everolimus.

MA

Wound healing complications. Results from an early study of high-exposure sirolimus (15–20ng/mL) with a 10mg/day loading dose in de novo kidney transplant patients raised

ED

concerns about wound healing complications compared to a conventional CNI-based regimen [83]. A subsequent meta-analysis of 37 studies undertaken in all organ types

PT

over a 13-year period found a higher incidence of wound complications and lymphoceles

CE

after kidney or heart transplantation in patients given mTOR inhibitor therapy [84]. In kidney transplantation specifically, a pooled analysis of three randomized studies of de

AC

novo everolimus (targeting 3–8ng/mL) versus MPA found the hazard ratio for wound healing complications using everolimus versus MMF to be 1.46 (95% CI 1.12, 1.90; p=0.005) [85]. In two of the studies, however, patients randomized to everolimus also received full-dose CNI, an approach which is no longer used.

Findings from the early days of high-exposure regimens, or with standard CNI therapy, may be of limited relevance. A more recent randomized controlled trial which included wound healing in the composite efficacy endpoint found no difference in healing rates after kidney transplantation when everolimus or MPA was given for the first four weeks post-transplant [22]. A recent review concluded that there is little evidence that modern concentration-controlled mTOR inhibitor regimens without a loading dose and

16

ACCEPTED MANUSCRIPT accompanied by reduced-exposure CNI result in a pronounced increase in wound healing events compared to a standard CNI-MPA regimen [86]. Concerns over wound

T

healing should not preclude the use of everolimus immediately after kidney

RI P

transplantation [87]. The exception appears to be patients with high body mass index (BMI) (>32kg/m2), who are already at heightened risk for impaired wound healing and in

SC

whom it seems prudent to avoid de novo everolimus or sirolimus [20, 83]. There is no evidence that mTOR inhibitors should be used cautiously in other groups who are more

NU

prone to wound healing complications, such as the elderly or patients with diabetes

MA

mellitus [86].

Proteinuria: Proteinuria is a frequent finding in kidney transplant patients, and has a

ED

complex etiology [88]. Switch from CNI therapy to an mTOR inhibitor has been associated with risk of proteinuria after kidney transplantation [89, 90], but a direct effect

PT

of mTOR inhibition is difficult to establish since CNI withdrawal can unmask pre-existing

CE

glomerular lesions [91]. Loss of CNI-induced renal vasoconstriction after conversion to an mTOR inhibitor is likely to contribute. One early study in heart transplantation

AC

showing a pronounced increase in albuminuria after CNI withdrawal with no introduction of mTOR inhibition [92], corroborated by the observation of more than a twofold increase in proteinuria in a series of 31 kidney transplant patients after CNI withdrawal [93]. However, there is also evidence that sirolimus may impair pathways essential for podocyte integrity [94] and contribute to podocyte injury at high doses [91], with risk of focal segmental glomerulosclerosis in kidney transplant patients [91].

The association between everolimus and protein excretion may depend on when everolimus therapy is started. In the large A2309 study, de novo initiation of everolimus (target 3–8ng/mL) and reduced-exposure CNI resulted in a similar urinary protein:creatinine ratio at month 12 to that seen with a conventional CNI-MPA regimen

17

ACCEPTED MANUSCRIPT (mean 35.6mg/g versus 31.1mg/g); rates of proteinuria reported as an adverse event were also similar [20]. In switch studies, studies of very early conversion to everolimus

T

have shown little difference in proteinuria parameters between everolimus- or CNI-

RI P

treated patients [27, 33]. There was a small but significant difference in the ZEUS trial where switch took place at 4.5 months post-transplant [34] then more substantial

SC

differences when conversion took place after several years [36, 37], and it could be speculated that grafts which have been exposed to immunological and non-

NU

immunological insults for longer are more vulnerable to development of proteinuria.

MA

It appears that de novo use of everolimus with reduced-CNI therapy after kidney transplantation does not influence risk of proteinuria, but more work is required to

ED

understand a possible effect following switch to mTOR inhibitors using contemporary regimens. The majority of trials in which patients are converted from CNI to everolimus

PT

have excluded patients with proteinuria >1g/day [34, 35, 36] or a urinary

AC

undocumented.

CE

protein:creatinine ratio ≥150mg/mmol [33, 37] and use in these settings is thus currently

Clinically, de novo glomerular protein after initiation of mTOR inhibitors is a clear sign of glomerular injury that should be monitored carefully, especially after late conversion from CNI therapy. It is sensible to perform renal biopsy before switching to an mTOR inhibitor to exclude pre-existing glomerular lesions, particularly focal segmental glomeruloslerosis, which could increase the risk of mTOR inhibitor-related injury.

Dyslipidemia. Establishing the effect of everolimus on lipid profiles in kidney transplant patients is complicated both by variations between studies in everolimus dosing and concomitant CNI therapy, and by differences in the use of lipid-lowering drugs. In a systematic review of 17 trials of mTOR inhibitor therapy in kidney transplantation,

18

ACCEPTED MANUSCRIPT Kasiske et al found higher levels of cholesterol or triglycerides under mTOR inhibitor therapy versus controls in all but one study, and a two-fold higher use of lipid-lowering

T

therapy [95], but the studies were from the period 1999–2007 and may not necessarily

RI P

reflect current practice. The effect of mTOR inhibitors on cholesterol levels appears to be dose-dependent [96], such that data from early high-dose trials may no longer apply.

SC

Moreover, it is difficult to discriminate between the hyperlipidemic effects of mTOR inhibitors and CNI therapy when used in combination. The B156 study showed that the

NU

incidence of hyperlipidemia in everolimus-treated patients was significantly lower with

MA

reduced-exposure CsA versus standard-exposure CsA (32.8% versus 52.8%, p<0.05) [17] i.e. trials which administered an mTOR inhibitor with standard CNI would be expected to show high rates of dyslipidemia due to a greater CNI-induced

ED

hyperlipidemia. Indeed, in a randomized trial by Bertoni et al, mean total cholesterol at

PT

month 12 showed little difference between patients receiving everolimus with very low CsA compared to MPA with standard CsA (5.7mmol/L versus 5.4mmol/L) [19]. Using

CE

more typical contemporary regimens, however, a hyperlipidemic effect is generally observed both with de novo everolimus plus reduced-exposure CNI [20] or after switch

AC

from CNI-based to everolimus-based immunosuppression [27, 33, 34, 36, 37]. While this is unlikely to be a barrier to use of everolimus, hyperlipidemia should be managed with the same vigor as in high-risk non-transplanted individuals.

Several of the key trials of everolimus in de novo kidney transplant patients [16, 17, 20, 23] have excluded patients with profound lipid abnormalities at the time of transplant, and everolimus from the time of transplant is thus largely unassessed in the presence of uncontrolled dyslipidemia. Conversion studies have only rarely excluded patients based on high lipid levels [33].

19

ACCEPTED MANUSCRIPT Hematological effects. A meta-analysis of mTOR inhibitors trials from 1996 to 2005 showed a significantly increased risk of leukopenia and thrombocytopenia compared to

T

CNIs [97], an effect which, it has been suggested [98], may not be dose-dependent.

RI P

When converting patients from CsA to everolimus, it is difficult to distinguish the effect of everolimus from the effect of higher MPA dosing after withdrawal of CsA [99], since MPA

SC

is known to have hematologic toxicity [100]. Some randomized trials of conversion from CNI to everolimus have reported a significant effect on white blood cell and/or platelet

NU

count following switch [34, 36, 41] while others have not [27, 37]. In the A2309 study,

MA

abnormal levels of white blood cells and platelets were in fact less frequent in de novo patients randomized to everolimus with reduced CNI than in the CNI-MPA group [20], presumably due to the effect of MPA in the control arm. Many randomized studies of

ED

everolimus in recent years have, however, excluded patients with severe hematological

PT

abnormalities at time of transplant [16, 20] or at time of switch [34, 36, 41, 42].

CE

Use mTOR inhibitor therapy may also adversely affect the risk of anemia [90] but low hemoglobin has not generally been an exclusion criterion for randomized trials or a

AC

reason to avoid switch to everolimus.

Conclusions

Immediate administration of everolimus post-transplant with reduced CNI, or subsequent switch to everolimus with CNI withdrawal, have been well-researched and offer potential advantages. Overall, for patients at low to moderate immunological risk, de novo use of everolimus with reduced CNI may be a preferable strategy, avoiding high-exposure CNI in the early weeks post-treatment and the risk of rejection following conversion. For patients with pre-transplant malignancy, or at high risk for CMV infection, this is a particularly appealing option. In certain categories of patients, de novo everolimus

20

ACCEPTED MANUSCRIPT should not generally be given – for example in those with uncontrolled hyperlipidemia or severe hematologic abnormalities at time of transplant, or in very obese patients at high

T

risk of wound healing (Table 4). Since a significant improvement in renal function has

RI P

been observed only when CNI exposure is reduced further than usual in everolimustreated patients [19], it will be interesting in future trials to explore more aggressive CNI

SC

lowering.

NU

Early switch from CNI to everolimus (<2 months) should not be undertaken due to the high risk of rejection [27, 33]. Safe but advantageous conversion with CNI withdrawal

MA

appears to be restricted to a window of three to six months after transplantation, and in patients with good renal function at the time of switch, but discontinuation rates are high.

ED

Many centers are, understandably, reluctant to disrupt the immunosuppression regimen during this relatively early period if the graft is functioning well. Later switch (>6 months),

PT

however, does not usually preserve renal function compared to a conventional CNI-

CE

based regimen and is largely unproductive unless the patient has good renal function, in which case there is little imperative to switch. Initiation of everolimus as rescue therapy

AC

in response to deteriorating graft function or other clinical indications such as malignancy can be helpful in individual cases but as in so many other areas of medicine, prevention would be regarded as preferable to ‘cure’.

The balance of evidence suggests two options. First, de novo everolimus with reduced CNI, steroids and induction therapy ensures immunosuppressive efficacy from the time of transplant, and although renal benefit remains to be convincingly demonstrated, lowers chronic CNI exposure significantly. This approach may be optimal in patients at low or standard immunological risk, and has not been assessed in high-risk individuals. If wound healing is of concern, for example in patients with very high BMI or with diabetes, introduction of everolimus could be delayed. The second option is to switch

21

ACCEPTED MANUSCRIPT patients to everolimus with CNI withdrawal between three and six months posttransplant, a strategy which offers a long-term renoprotective effect if baseline graft

AC

CE

PT

ED

MA

NU

SC

RI P

T

function is good and the new regimen is tolerated.

22

ACCEPTED MANUSCRIPT References

7.

8.

9.

10.

11. 12.

13.

14.

15.

16.

17.

T

RI P

SC

NU

6.

MA

5.

ED

4.

PT

3.

CE

2.

Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011;22:2107–18. Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation 2012;94:659–68. Dantal J. Everolimus: preventing organ rejection in adult kidney transplant recipients. Expert Opin Pharmacother 2012;13:767–78. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997;64:32–5. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage and future directions. Transplant Rev 2006;20:1–18. Gutiérrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in posttransplant malignancies. Nephrol Dial Transplant 2007;22(Suppl 1):i11–6. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581–9. Euvrard S, Boissonnat P, Roussoulières A, et al. Effect of everolimus on skin cancers in calcineurin inhibitor-treated heart transplant recipients. Transpl Int 2010;23:855–7. Zeier M, Van Der Giet M. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation? Transpl Int 2011;24:30–42. Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 2008;52:324–30. Tarantino G, Capone D. Inhibition of the mTOR pathway: a possible protective role in coronary artery disease. Ann Med 2013;45:348–56. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011;1:2453–62. Ekberg H, Tedesco-Silva H, Demirbas A, et al; ELITE-Symphony Study Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562–75. Durrbach A, Rostaing L, Tricot L et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008;85:486–90. Langer RM, Hené R, Vitko S, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int 2012;25:592–602. Chan L, Greenstein S, Hardy MA, et al: Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008, 85:821 Nashan B, Curtis J, Ponticelli C, et al on behalf of the 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a threeyear Phase II, randomized, multicenter, open-label study. Transplantation 2004; 78:1332–40.

AC

1.

23

ACCEPTED MANUSCRIPT

AC

CE

PT

ED

MA

NU

SC

RI P

T

18. Qazi Y, Shaffer D, Kaplan B, et al. Efficacy and safety of everolimus with low-dose tacrolimus in de novo renal transplant recipients; 12-month randomized study. Am J Transplant 2014;14(Suppl 3):80 [Abstract 713] 19. Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. J Nephrol 2011;24:613–8. 20. Tedesco Silva Jr H, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010;10:1401–13. 21. Cibrik D, Silva HT Jr, Vathsala A, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013;95:933–942. 22. Albano L, Berthoux F, Moal MC, et al; RAD A2420 Study Group: Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009, 88:69 23. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009;88:1194–1202. 24. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004;4:626–35. 25. Shihab FS, Cibrik D, Chan L, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant 2013;27:217–26. 26. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557–65. 27. Chadban SJ, Eris JM, Kanellis J, et al; SOCRATES Study Group. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int 2014;27:302–11. 28. Montagnino G, Sandrini S, Iorio B, et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008;23:707–14. 29. Pascual J, Srinivas TR, Chadban S, et al. TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. Open Access J Clin Trials 2014:6:45–54. 30. Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006;38:3456–8. 31. Brandhorst G, Tenderich G, Zittermann A, et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 2008;30:113–6. 32. Rostaing L, Christiaans MH, Kovarik JM, Pascual J. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. Ann Transplant 2014;19:337–45. 33. Mjörnstedt L, Sørensen SS, von Zur Mühlen B, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 2012;12:2744–53.

24

ACCEPTED MANUSCRIPT

AC

CE

PT

ED

MA

NU

SC

RI P

T

34. Budde K, Becker T, Arns W, et al; for ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011;377:837–47. 35. Budde K, Witzke O, Lehner F, et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: The HERAKLES Study. Transplantation 2012;94(Suppl):993 [Abstract]. 36. Budde K, Rath T, Sommerer C, et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clin Nephrol 2015;83:11–21. 37. Holdaas H, Rostaing L, Serón D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation 2011;92:410–418. 38. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012;12:1192–8. 39. Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: The randomized ZEUS study. Am J Transplant 2015;15:119–28. 40. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242 41. Mjörnstedt L, Sørensen SS, von zur Mühlen B, et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: Results from a randomized trial in kidney transplantation. Transplant Int 2015; 28: 42–51 42. Budde K, Sommerer C, Rath T, et al. Renal function to five years after late conversion of kidney transplant patients to everolimus: A randomized trial. J Nephrol 2015;28:115–23. 43. Budde K, Arns W, Sommerer C, et al. Superior renal function in an everolimusbased calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: Follow-up of the HERAKLES Study at month 36. Am J Transplant 2014;14(Suppl 3):81 [Abstract 716]. 44. Zeier M, Budde K, Arns W, et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: Month 36 follow-up results of the HERAKLES trial. Am J Transplant 2014;14(Suppl 3):81 [Abstract 718]. 45. Inza A, Balda S, Alvarez E, Zárraga S, Gaínza FJ, Lampreabe I. Conversion to everolimus in kidney transplant recipients with decreased renal function. Transplant Proc 2009;41:2134–6. 46. Pape L, Ahlenstiel T, Ehrich JH, Offner G. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant 2007;11:291–5. 47. de fijter JW. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007;22(Suppl 1):i23–6. 48. Caroti L, Zanazzi M, Paudice N, et al. Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin. Transplant Proc 2012;44:1926–7. 49. Chiurchiu C, Carreño CA, Schiavelli R, et al. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc 2010;42:277–9.

25

ACCEPTED MANUSCRIPT

AC

CE

PT

ED

MA

NU

SC

RI P

T

50. Fernández A, Marcén R, Pascual J, et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 2006;38:2453–5. 51. Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A. Conversion to everolimus in kidney transplant recipients: to believe or not believe? Transplant Proc 2012; 44:2966–70. 52. Sahin S, Gürkan A, Uyar M, et al. Conversion to proliferation signal inhibitors-based immunosuppressive regimen in kidney transplantation: to whom and when? Transplant Proc 2012;44:1926–7. 53. Sola E, Lopez V, Gutierrez C, et al. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years. Transplant Proc 2010;42:2859–60. 54. Fernández A, Marcén R, Galeano C, et al. Complete switch to everolimus in longterm kidney transplants: evolution of the renal function. Transplant Proc 2009;41:2345–7. 55. Kobashigawa JA, Pauly DF, Starling RC, et al. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart Fail 2013;1:389–99. 56. Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008;26:2213–9. 57. Joannidès R, Monteil C, de Ligny BH, et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant 2011;11:2414–22. 58. Paoletti E, Ratto E, Bellino D, Marsano L, Cassottana P, Cannella G. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction. J Nephrol 2012;25:709–18. 59. Sułkowska K, Palczewski P, Miszewska-Szyszkowska D, Durlik M, Gołębiowski M, Małkowski P. Early everolimus-induced pneumonitis in a renal transplant recipient: A case report. Ann Transplant 2012;17:144–8. 60. Errasti P, Izquierdo D, Martín P, et al. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc 2010;42:3053–4. 61. Lopez P, Kohler S, Dimri S. Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: Results from a large Phase III clinical trial program of everolimus and review of the literature. J Transplant 2014;2014:305931. 62. Mahé E, Morelon E, Lechaton S, Kreis H, de Prost Y, Bodemer C. Angioedema in renal transplant recipients on sirolimus. Dermatology 2007;214:205–9. 63. Wadei H, Gruber SA, El-Amm JM, et al. Sirolimus-induced angioedema. Am J Transplant 2004;4:1002–5. 64. Rigol M, Solanes N, Sionis A, et al. Effects of cyclosporine, tacrolimus and sirolimus on vascular changes related to immune response. J Heart Lung Transplant 2008;27: 416–22. 65. Haneda M, Owaki M, Kuzuya T, Iwasaki K, Miwa Y, Kobayashi T. Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone.Transplantation 2014;97:405–12. 66. Sommerer C, Morath C, Shaier M, Süsal C, Zeier M. Is there an increased risk of de novo donor specific HLA antibodies in calcineurin-inhibitor sparing immunosuppression? J Am Soc Nephrol 2013;24(Suppl):598A.

26

ACCEPTED MANUSCRIPT

AC

CE

PT

ED

MA

NU

SC

RI P

T

67. Pascual J, Arns W. Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients? Am J Transplant 2012;12:2561–2. 68. Kamar N, Del Bello A, Congy-Jolivet N, et al. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. Clin Transplant 2013;27:455–62. 69. Croze LE, Tetaz R, Roustit M, et al. Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. Transpl Int 2014;27 775–83. 70. Sánchez-Fructuoso AI, Santiago JL, Pérez-Flores I, Calvo Romero N, Valero R. De novo anti-HLA antibodies in renal allograft recipients: a cross-section study. Transplant Proc 2010;42:2874–6. 71. Havenith SH, Yong SL, van Donselaar-van der Pant KA, van Lier RA, ten Berge IJ, Bemelman FJ. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation 2013;95:184–91. 72. Keven K, Sahin M, Kutlay S, et al. Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and azathioprine. Transpl Infect Dis 2003;5:181–6. 73. Jin N, Malcherek G, Mani J, et al. Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus. Leuk Lymphoma 2014;55:1144–50. 74. Johnson RA, Wang X, Ma XL, Huong SM, Huang ES. Human cytomegalovirus upregulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001;75:6022– 32. 75. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012;93:1075–85. 76. Vítko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004;78:1532–40. 77. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244–52. 78. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007;84:1436–42. 79. Suwelack B, Malyar V, Koch M, Sester M, Sommerer C. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando) 2012;26:201–11. 80. Liacini A, Seamone ME, Muruve DA, Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection Transplantation 2010;90:1450–7. 81. Moscarelli L, Caroti L, Antognoli G, et al. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a singlecenter experience. Clin Transplant 2013;27:546–54. 82. Elfadawy N, Flechner SM, Schold JD, et al. Transient versus persistent BK viremia and long-term outcomes after kidney and kidney-pancreas transplantation. Clin J Am Soc Nephrol 2014;9:553–61. 83. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004;77:1555–61.

27

ACCEPTED MANUSCRIPT

AC

CE

PT

ED

MA

NU

SC

RI P

T

84. Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int 2011;24:1216–30. 85. Cooper M, Wiseman AC, Zibari G, et al. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials. Clin Transplant 2013;27:E625–35. 86. Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: A critical review of the literature. Transplantation 2012;94:547–61. 87. Holdaas H, Midtvedt K, Åsberg A. A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf 2012;11:1013–22. 88. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transpl Int 2012;25:909–17. 89. Diekmann F, Andrés A, Oppenheimer F. mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 2012;26:27–9. 90. Murakami N, Riella LV, Funakoshi T. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and metaanalysis. Am J Transplant 2014;14:2317–27. 91. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 2008;22:125–30. 92. Myers BD, Sibley R, Newton L et al. The long-term course of cyclosporineassociated chronic nephropathy. Kidney Int 1988;33:590–600. 93. Ducloux D, Motte G, Billerey C et al. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a two-year follow-up. Transplant Int 2002;15:387–92. 94. Letavernier E, Bruneval P, Vandermeersch S et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009;24:630–8. 95. Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008;8:1384– 92. 96. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002;2:551–9. 97. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006;81:1234–48. 98. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range Transplantation 2002;73:920–5. 99. Cortinovis M, Gotti E, Pradini S, Gaspari F, Perico N. Renal graft function and lowdose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. Transplantation 2011;92:550–6. 100. Vanhove T, Kuypers D, Claes KJ, et al. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transpl Int 2013;26:813–21.

28

ACCEPTED MANUSCRIPT

Risk status

Intervention regimen

Control regimen

Yes/no

a

Induction

Duration (months)

BAS or rATG

US09 [16]

92

Low or moderate

EVR 3-8 ng/mL TAC reduced to 1.5-3 ng/mL from month 4

EVR >3 ng/mL + reduced TAC

PT

Low or moderate

EVR 3-8 ng/mL TAC continue d at 4-7 ng/mL from month 4

Yes

EVR >3 ng/mL + standard TAC

Yes

CE

224

BAS

EVR + reduced TAC EVR + standard TAC

12

AC

ASSET [15]

Treatment group

12

ED

EVR + reduced CNI versus EVR + standard CNI US92 613 All EVR 3-8 EVR 3-8 [Abstract] ng/mL + ng/mL + [18] reduced standard TAC TAC

Steroid therapy

CR

n

MA NU S

Study

IP

T

Table 1. Randomized trials of de novo everolimus with reduced-exposure CNI in kidney transplant patients. All between-group differences were non-significant, or not tested statistically, unless otherwise stated

EVR + reduced TAC EVR + standard TAC BAS

6

Composite efficacy endpoint

BPAR

Renal function

Composite efficacy b failure

Treated BPAR

24.6%

19.1%

Mean eGFR (MDRD), mL/min/1.73 2 m 63.1

-

20.4%

11.2%

63.1

-

-

BPAR months 4-12

Mean eGFR (MDRD), mL/min/1.73 2 m d 57.1

17.4%

51.7

10.1%

Mean eGFR (Nankivell), mL/min/1.73 2 m d 75.3

9%

2.7%

-

d

1.1%

-

EVR + reduced

-

14%

d

c

Discontinuation due to adverse events

29

ACCEPTED MANUSCRIPT

EVR ≥3 ng/mL + standard CsA

BAS

36

Yes

BAS

833

Low or moderate

EVR 3-8 ng/mL or EVL 6-12 ng/mL + reduced CsA

MPA + standard CsA

Yes/no

a

BAS

-

14%

72.5

10%

17.2% (p=0.032)

12.1%

CrCl (CockcroftGault), mL/min d 57

17.2%

35.8%

18.9%

52

39.6%

Composite efficacy e failure

-

EVR + very reduced CsA MPA + standard CsA

AC A2309 [20, 21]

EVR ≥3ng/mL + reduced CsA EVR 3ng/mL + standard CsA

12

CE

EVR + reduced CNI versus MPA + standard CNI Bertoni 106 Low or EVR 8-12 MPA + 2011 [19] moderate ng/mL + standard very CsA reduced CsA

Yes

CR

EVR ≥3 ng/mL + reduced CsA

MA NU S

Low or moderate

ED

111

PT

B156 [17]

IP

T

TAC EVR + standard TAC

24

EVR 38ng/mL + reduced CsA

Mean CrCl (CockcroftGault), mL/min 81.6 (p<0.001 )

-

18.5%

-

18.2%

62.6

Composite efficacy failure at b month 12

Treated BPAR at month 24 19.9%

Mean eGFR (MDRD), mL/min/1.73 2 m

25.3%

f

f

52.5

-

-

28.5% (p=0.003 vs MPA)

30

ACCEPTED MANUSCRIPT

21.9%

f

f

15.1%

49.4

30.6% (p=0.007 vs MPA)

24.2%

19.1%

50.5

20.5%

Composite efficacy e endpoint

BPAR

21.5%

10.8%

Mean eGFR (Nankivell), mL/min/1.73 2 m d 52.7

20.0%

9.5%

48.8

23.0%

-

14.0%

Mean CrCl (CockcroftGault), mL/min d 59.9

4.9%

-

11.3%

57.8

2.8%

High risk for DGF

EVR 3-8 ng/mL + reduced CsA

MPA to week 4 + standard CsA then switch to EVR + reduced CsA

Yes

EVR 3-8 ng/mL + reduced CsA

EVR 812 ng/mL + very reduced CsA

Yes

CE

Low or moderate

AC

285

PT

EVR + very reduced CNI vs EVR + reduced CNI EVEREST [23]

±IL-2RA

3

MA NU S

139

ED

CALLISTO [22]

CR

IP

T

EVR 6-12 ng/mL + reduced CsA MPA + standard CsA

BAS

EVR + reduced CsA MPA + standard CsA

6

18.9%

f

d

-

EVR 3-8 ng/mL + reduced CsA EVR 8-12 ng/mL + very reduced CsA

f

BAS, basiliximab; BPAR, biopsy-proven acute rejection; CNI, calcineurin inhibitor; CrCl, creatinine clearance; CsA, cyclosporine; eGFR, estimated GFR; EVR, everolimus; IL-2RA, interleukin-2 receptor antagonist; MDRD, Modification of Diet in Renal Disease; MPA, mycophenolic acid; rATG, rabbit antithymocyte globulin

31

ACCEPTED MANUSCRIPT

a

According to local practice Treated BPAR, graft loss, death or loss to follow-up c Significantly higher than the control group (% difference 7.9%, 95% CI 2.3, 13.5%) d Non-significant difference versus the control group e BPAR, graft loss, death or loss to follow-up f Statistically non-inferior to the control group

AC

CE

PT

ED

MA NU S

CR

IP

T

b

32

ACCEPTED MANUSCRIPT

126

2 weeks

202

7 weeks

Steroids

EVR 6-10 ng/mL+ MPA

CsA + MPA

Yes

EVR 6-10 ng/mL + MPA

CsA + MPA

Followup (months postRDZ) 11.5

Yes

HERAKLES

300

499

4.5

3

AC

ZEUS [34]

EVR 6-10 ng/mL + MPA

EVR 5-10

CsA + MPA

CsA +

Treatment group

EVR + MPA CsA + MPA

EVR + MPA CsA + MPA Yes

Yes

BPAR postRDZ

31% (p=0.04 8) 13%

10

CE

CENTRAL [33]

a

Control regimen

CR

SOCRATES [27]

Switch regimen

MA NU S

Time of RDZ (months post-tx)

ED

n

PT

Study

IP

T

Table 2. Randomized trials of pre-emptive switch to everolimus with no CNI or reduced-exposure CNI in kidney transplant patients. All between-group differences were non-significant, or not tested statistically, unless otherwise stated

27.5 % (p=0.00 4) 11.0%

7.5

9

EVR + MPA

9.7% (p=0.03 6)

CsA + MPA

3.4%

Renal function

Discontinuation due to adverse events

Mean eGFR (Nankivell), mL/min/1.73 2 m b 65.1

30.6%%

67.1

8.5%

Mean change in mGFR, mL/min 4.6 (p=0.012)

25.5% (p=0.030)

0.0

3.0%

Mean eGFR (Nankivell, mL/min/1.73 2 m) c 71.8

6.5%

61.9

2.1%

Mean eGFR

33

ACCEPTED MANUSCRIPT

Mean 67

10.0%

EVR + CsA CsA+ MPA

8.5% 8.4%

63.0

T EVR + MPA

(Nankivell, mL/min/1.73 2 m) 68.6 (p=0.0001 vs CsA + MPA) 63.1

IP CR

EVR 8-12 ng/mL + MPA or EVR 3-8 ng/mL + reduced CsA

MA NU S

EVR 6-10 ng/mL + MPA

CsA + MPA

CsA + MPA

Yes/no

ED

394

Mean 83.5

AC

ASCERTAI N [37]

93

MPA

PT

APOLLO [36]

ng/mL + MPA Or EVR 3-8 ng/mL + CsA

CE

[35]

Yes

d

12

-

-

-

Mean eGFR (Nankivell), mL/min/1.73 2 m EVR + MPA CsA + MPA

0%

61.6

32.6%

0%

58.8

10.6%

5.7%

Mean mGFR, mL/min 48.0

5.6%

46.6

16.7 (p=0.020)

2.5%

46.0

4.1

24 EVR 812ng/mL + MPA EVR 38ng/mL + CsA CsA + MPA

28.3 (p<0.001)

a

CNI reduced by 50% from week 2 to month 2 then withdrawn Statistically non-inferior to the control group c 2 2 Significantly higher than the control group (mean difference 9.8 mL/min/1.73m , 95% CI -12.2 to -7.5 mL/min/1.73m ) d According to local practice BPAR, biopsy-proven acute rejection; CNI, calcineurin inhibitor; CsA, cyclosporine; eGFR, estimated GFR; EVR, everolimus; mGFR, measured GFR; MPA, mycophenolic acid; RDZ, randomizaton; tx, transplant b

34

ACCEPTED MANUSCRIPT

182/ 202

269/ 300

Control regimen

Steroids

7 weeks

EVR 6-10 ng/mL + MPA

CsA + MPA

Yes

4.5

EVR 6-10 ng/mL + MPA

CsA + MPA

Longterm follow-up (months postRDZ) 34

Yes

APOLLO [42]

78/93

3

EVR 5-10 ng/mL + MPA Or EVR 3-8 ng/mL + CsA

CE

376/ 499

CsA + MPA

Yes

Mean 83.5

EVR 6-10 ng/mL + MPA

CsA + MPA

Yes/no

BPAR post-RDZ

Renal function to last followup

Months 1236

Change in mGFR, mL/min 1.3 (p=0.210) -1.7 Mean eGFR (Nankivell, mL/min/1.73 2 m) 66.7 (p=0.004)

EVR + MPA CsA + MPA

13.0% 11.1%

EVR + MPA

13.6% (p=0.095)

CsA + MPA

7.5%

EVR + MPA

15%

EVR + CsA CsA+ MPA

14% 13%

33

AC

HERAKLES [43, 44]

Treatment group

43.5

PT

ZEUS [39]

Switch regimen

CR

CENTRAL [41]

Time of RDZ(mont hs post-tx)

MA NU S

n/N

ED

a

Study

IP

T

Table 3. Long-term follow-up data from randomized trials of pre-emptive switch to everolimus with no CNI or reduced-exposure CNI in kidney transplant patients. All between-group differences were non-significant, or not tested statistically, unless otherwise stated

b

60

60.4 Mean eGFR (Nankivell, mL/min/1.73 2 m) 62.6 (p=0.009 vs CsA + MPA) 54.6 55.6 Mean eGFR (Nankivell), mL/min/1.73 2 m

35

ACCEPTED MANUSCRIPT

T

EVR + MPA

0%

63.0 (p=0.076) 57.6

CR

IP

CsA + MPA

0%

PT

ED

Number of patients entering follow-up study/number of patients randomized According to local practice

CE

b

AC

a

MA NU S

BPAR, biopsy-proven acute rejection; CNI, calcineurin inhibitor; CsA, cyclosporine; eGFR, estimated GFR; EVR, everolimus; mGFR, measured GFR; MPA, mycophenolic acid; RDZ, randomizaton; tx, transplant

36

ACCEPTED MANUSCRIPT Table 4. Patient characteristics influencing choice of everolimus regimen in kidney transplant recipients

Not assessed

Low to moderate immunological risk

Substantial (>60%) reduction in CNI exposure with no additional risk of acute rejection

≤6 months post-transplant

n.a.

>6 months post-transplant

n.a.

Poor renal function (e.g. CrCl <50mL/min or eGFR <40 2 mL/min/1.73 [Nankivell]) CMV- recipient/CMV+ donor

n.a.

Pre-transplant malignancy

PT

Proteinuria >1g/day or urinary protein:creatinine ratio ≥150 mg/mmol Uncontrolled hyperlipidemia Severe leukopenia or thrombocytopenia

SC NU MA

2

May reduce risk of CMV events Avoid due to risk of wound healing complications May reduce risk of posttransplant malignancy n.a.

ED

BMI >32kgm

RI P

High immunological risk

Pre-emptive switch from CNI to EVR May be inadvisable due to risk of rejection Significant renal improvement if <6 months post-transplant or good baseline renal function but risk of mild rejection Significant renal improvement but risk of mild rejection Renal improvement only if baseline renal function is good Unlikely to show a renal benefit

T

De novo EVR + reduced CNI

Delay switch if surgery is planned Not assessed Risk of exacerbating existing proteinuria Not assessed Not assessed

CE

Not assessed Not assessed

n.a.

AC

BMI, body mass index; CMV, cytomegalovirus; CrCl, creatinine clearance; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; EVR, everolimus; n.a., not applicable

37